About this trial
Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and transdifferentiation potential. Little is known about the molecular mechanisms governing TCP in lung adenocarcinoma (LUAD), i.e. the most frequent lung cancer subtype. The investigators recently identified prognostic 7-miRNAs/10-mRNAs signatures which accurately identified aggressive LUAD among patients with early-stage disease (Stage I). Furthermore, the investigators showed that such tumors show TCP features i.e. mesenchymal and stem-cell traits, high-metastatic potential. Here, the investigators aim to explore by RNAseq and by immunophenotyping at a single-cell level (scRNAseq/AbSeq), the molecular features of aggressive LUAD to unveil the mechanisms triggering TCP. The investigators predict thier results will be relevant for the development of more effective therapeutic protocols for management of aggressive LUAD.
Eligibility criteria
Qualifiers
patients diagnosed with lung adenocarcinoma
treatment naive
undergoing primary surgery
Disqualifiers
patients with a previous history of cancer
previously treated by chemio/immuno/radio-therapy
Trial design
Treatments tested in this trial
- Analysis of diagnostic biomarkers
Treatment groups
Locations
Sponsors and collaborators
Casa Sollievo della Sofferenza IRCCS
Lead sponsor
IRCCS Ospedale San Raffaele
Collaborator